PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 29 filers reported holding PHARVARIS N V in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $98,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $56,675,833 | 27.86% |
| venBio Partners LLC | 4,264,672 | $64,567,134 | 23.37% |
| Bain Capital Life Sciences Investors, LLC | 4,868,784 | $73,713,390 | 7.59% |
| VR Adviser, LLC | 1,326,200 | $20,078,668 | 3.21% |
| 5AM Venture Management, LLC | 587,600 | $8,896,264 | 2.22% |
| Novo Holdings A/S | 1,329,325 | $20,125,981 | 1.56% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $66,710,655 | 1.05% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $3,028,000 | 0.94% |
| Cormorant Asset Management, LP | 973,614 | $14,740,516 | 0.83% |
| Soleus Capital Management, L.P. | 391,900 | $5,933,366 | 0.66% |